Cancer Immunotherapy and Biomarkers

This study identifies Mettl3-m6A methylation as a regulator of CD8+ T cell differentiation fate in tumors, showing its role in promoting terminal exhaustion and its potential as a target to enhance immunotherapy.

The paper compares T-cell counts and spatial patterns in colorectal adenomas and sessile serrated lesions, finding differences in T-cell infiltration and clustering by lesion type.

This study develops a cell-permeable morpholino ASO targeting PD-L1 in breast cancer, which reduces PD-L1 expression and enhances antitumor immunity when combined with durvalumab.

This study shows TMEM33 limits progenitor-exhausted CD8+ T cells, enhances anti-tumor responses, and correlates with improved survival in melanoma patients.

This study investigates how APOBEC mutagenesis and A3B deletion affect immune activation in Asian breast cancer using spatial transcriptomics, finding that mitochondrial mutations and cGAS-STING pathway activation drive immune responses instead of neoantigens.

This study identifies MELK as a key driver of metabolic adaptation and therapy resistance in melanoma, showing that inhibiting MELK can sensitize resistant cells to immunotherapy.

The paper identifies tetrads as a multicellular immune unit that correlates with antitumor immunity and response to checkpoint blockade in mouse and human tumors.

This study maps spatial immune heterogeneity in luminal breast cancer, showing progressive immunosuppression from tumor margins to core.

This study identifies clonal persistence, tertiary lymphoid structures (TLS) engagement, and coordinated B-T cell immune surveillance as hallmarks of durable tumour control in a long-term survivor of metastatic ccRCC.

The paper identifies collagen remodeling as a mechanism that activates a GPCR-mediated immune checkpoint in ADGRG1+ CD8+ T cells, influencing response to immunotherapy.

This study shows PKMYT1 inhibition causes DNA damage and enhances anti-PD-1 therapy in CCNE1-amplified gastroesophageal adenocarcinoma.

The paper identifies Treg-CD8 T cell interactions in the sentinel lymph node as predictors of melanoma recurrence in Stage II patients.

This study shows that combining PD-L1 and TIGIT blockade in a mouse model of rhabdoid tumors leads to tumor regression by promoting immune cell recruitment and vascular changes.

The paper identifies co-expression patterns of chemokine receptors on CD8+ T cells that distinguish anti-tumor efficacy from off-target toxicity in melanoma.

This paper introduces HINS, a deep-learning method that predicts immune checkpoint blockade response using HLA-mediated immunogenic neoantigen scores, achieving high accuracy in identifying responders.

The paper uses patient tumor samples to identify lineage- and context-specific mechanisms of innate immune resistance through perturbational single-cell RNA sequencing.

This study shows that isoflavones in the diet impair anti-PD1 therapy response in breast cancer models, regardless of dietary fiber or SCFA levels, and that ER blockade can restore responsiveness.

This study shows that inhibiting nonsense-mediated mRNA decay enhances tumour immunogenicity, drives immunoediting, and improves checkpoint blockade efficacy in preclinical models.

This study develops antibody-peptide epitope conjugates (APECs) to enhance anti-tumor activity in ICB-resistant HNSCC by leveraging viral peptide-loaded MHC I proteins and protease activity.

This study uses single-cell RNA sequencing to analyze immune and stromal differences between primary tumors and metastatic lymph nodes in ESCC, revealing distinct exhaustion trajectories and suppressive circuits.

This study shows PD-1 blockade during T cell priming promotes an intermediate-exhausted CD8 T cell state that supports durable anti-tumor immunity after surgery and metastatic challenge, better than effector or memory-like T cells.

This study links oncogenic RAS activity to immune priming and adenosine-driven immune evasion in lung adenocarcinoma, showing both pro-immunogenic and immunosuppressive effects.

The paper identifies riboflavin-auxotrophic Enterococcus spp. that synergize with metabolites to boost MR1 expression and activate MAIT cells in the tumor microenvironment.

This study shows TAp73 regulates lipid metabolism in lung tumor microenvironment to enhance anti-tumor immunity through T-cell activation.

This paper identifies NOTCH1 and MYB as dual transcriptional drivers of immune suppression in salivary adenoid cystic carcinoma, revealing their roles in suppressing T-cell and B-cell immunity through distinct signaling pathways.

This study shows that aging reduces T cell recruitment in breast cancer by decreasing Cxcl9/Cxcl10 expression in tumor cells, leading to weakened anti-tumor immunity.

This study shows that targeting the STING-ATM axis with a STING agonist overcomes radiotherapy-induced immune suppression in nasopharyngeal carcinoma, enhancing anti-tumor immunity and tumor control.

This study identifies microbiome-derived protein biomarkers for predicting immunotherapy response and toxicity in melanoma without relying on taxonomic classification.